29.03.2020, 869 Zeichen

Valneva: Valneva SE, a specialty vaccine company, is cognizant of the impact of the COVID-19 outbreak on the travel market. As the provider of two travel vaccines, one against Japanese encephalitis and one against cholera/ETEC, the Company expects that its 2020 revenues may be adversely affected. The Company estimates that 2020 product sales revenues could be impacted by between Euro 20 mn and Euro 40 mn (compared to guidance of 125 mn to 135 mn announced previously). This reduction in product sales revenue, offset by the likely delay in chikungunya Phase 3 initiation and therefore delay of initial Phase 3 costs, may lead to negative EBITDA of up to €50 million in 2020 compared to earlier guidance of negative EBITDA of up to €35 million.
Valneva: weekly performance: -6.78%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/03/2020)

Christian Drastil: Wiener Börse Plausch

Kapitalmarkt-stimme.at daily voice: Mit 50 abgeschrieben? Dann tu was dagegen! (CD liest Andrea Lehwald)

Bildnachweis

Aktien auf dem Radar:AT&S, UBM, Strabag, Zumtobel, Lenzing, Agrana, Uniqa, Wolford, RBI, OMV, Porr, Palfinger, Fabasoft, Rosgix, Erste Group, Kapsch TrafficCom, Polytec Group, Wiener Privatbank, Warimpex, Frauenthal, BKS Bank Stamm, Oberbank AG Stamm, Amag, CA Immo, EuroTeleSites AG, CPI Europe AG, Österreichische Post, Semperit, Telekom Austria, Deutsche Post, Caterpillar.

---